Collegium Pharmaceutical (COLL) Change in Accured Expenses (2014 - 2026)

Collegium Pharmaceutical has reported Change in Accured Expenses for 13 years, with the latest figure at $12.3 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 119.71% year-over-year to $12.3 million in Q2 2026; TTM through Jun 2026 was $10.7 million, a 120.37% increase from a year earlier, with the FY2025 full-year figure at -$9.5 million, up 75.98% from the prior year.
• Change in Accured Expenses was $12.3 million for Q2 2026 at Collegium Pharmaceutical, up from -$4.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $22.4 million in Q4 2024, with the low at -$62.9 million in Q3 2024.
• Average Change in Accured Expenses over 5 years is -$2.9 million, with a median of -$249500.0 recorded in 2022.
• The largest YoY upside for Change in Accured Expenses was 1635.09% in 2025 against a maximum downside of 2777.73% in 2025.
• Over 5 years, Change in Accured Expenses stood at $13.6 million in 2022, then tumbled by 62.42% to $5.1 million in 2023, then surged by 339.04% to $22.4 million in 2024, then tumbled by 52.26% to $10.7 million in 2025, then increased by 14.67% to $12.3 million in 2026.
• The last three Change in Accured Expenses figures came in at $12.3 million (Q2 2026), -$4.2 million (Q1 2026), and $10.7 million (Q4 2025), per Business Quant data.